Return to Press Releases
NUCRYST Pharmaceuticals appoints Edward Gaj Jr.
Vice President, Corporate Development
WAKEFIELD, Massachusetts, June 4, 2007 – NUCRYST Pharmaceuticals Corp. (NASDAQ: NCST; TSX: NCS) today announced that Edward Gaj Jr. has been appointed Vice President, Corporate Development. He will be responsible for leading NUCRYST’s corporate partnering initiatives, strategic planning, corporate communications and patent portfolio management.
“Ed brings a wealth of experience in the pharmaceutical industry and he will add to the bench strength of our senior management team,” said Scott H. Gillis, President and CEO of NUCRYST. “With his successful track record of technology and product licensing leading to business growth, he will play a pivotal role in advancing our partnering initiatives and corporate development.”
Since 1998, Mr. Gaj held a series of progressively senior positions at Anika Therapeutics including Director and Executive Director, Marketing and Business Development and most recently, Franchise Director, Aesthetics. Mr. Gaj has considerable knowledge and experience developing licensing and commercialization strategies, structuring and negotiating agreements and running all aspects of a key business unit.
Previously, Mr. Gaj was with B&E Consulting, where he was responsible for new business opportunity assessment and development for clients. He also held positions at Immunologic Pharmaceutical Corp, Biogen, Alpha Therapeutics Corp and Lederle Laboratories. He started his career as an oncology pharmacist at the New England Deaconess Hospital and a staff pharmacist at the Lahey Clinic.
Mr. Gaj earned a BS and MS at the Massachusetts College of Pharmacy and is a registered pharmacist.
NUCRYST Pharmaceuticals (NASDAQ: NCST; TSX: NCS) develops, manufactures and commercializes medical products that fight infection and inflammation using its patented atomically disordered nanocrystalline silver technology. Smith & Nephew plc sell a range of advanced wound care products under their Acticoat™ trade mark: Acticoat™ products incorporate NUCRYST’s SILCRYST™ coatings and are sold in over 30 countries. NUCRYST is also developing pharmaceutical products to address medical conditions that are characterized by both infection and inflammation. The company has developed its proprietary nanocrystalline silver in a powder form for use as an active pharmaceutical ingredient, referred to as NPI 32101.
Acticoat™ is a trademark of Smith & Nephew plc
For more information contact:
SILCRYST™ is a trademark of NUCRYST Pharmaceuticals Corp.
This news release may contain forward-looking statements within the meaning of securities legislation in the United States and Canada. These statements are based on current expectations that are subject to risks and uncertainties, and the Company can give no assurance that these expectations are correct. Various factors could cause actual results to differ materially from those projected in such statements, including but not limited to: the initiation, timing, progress and results of our preclinical and clinical trials, research and development programs; our ability to implement our business model and strategic plans for our business, product candidates and technology; our ability to maintain and establish corporate collaborations; changes in general economic conditions; financial considerations; other risks and uncertainties unidentified at this time; and management’s response to these factors. The Company disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Return to Press Releases